01 April 2019
Enamine Ltd. a provider of integrated drug discovery services empowered by the world’s largest collections of building blocks and screening compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical company involved in the research of new drugs for the treatment of disorders in the central nervous system, announced the expansion of their research collaboration. Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs.
Enamine’s REAL Database is allowing us to expedite our hit explosion programs at unmatched speed and synthesis success. We look forward to the results of our HTS campaigns and to continue receiving highly valuable compounds exclusively synthesized for us, Dr. Paul Kilburn, Director and Head of Medicinal Chemistry at Lundbeck said.
We are delighted to extend our collaboration with Lundbeck, with whom we have a strong historical relationship. This reflects the high-performance level already achieved and a confidence mutually shared, which is most gratifying, Michael Bossert, Head of Strategic Alliances at Enamine, commented.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024